Results 21 to 30 of about 3,892 (211)

Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs

Frontiers in Psychiatry, 2017
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects.
Zurina Hassan, Oliver G. Bosch, Darshan Singh, Suresh Narayanan, B. Vicknasingam Kasinather, Erich Seifritz, Johannes Kornhuber, Boris B. Quednow, Christian P. Müller   +8 more
doaj   +1 more source

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience

Frontiers in Pharmacology, 2016
The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance.
Andrew Robert Gallimore, Rick Strassman
doaj   +1 more source

Pharmacokinetics of N,N-dimethyltryptamine in Humans

European Journal of Drug Metabolism and Pharmacokinetics, 2023
N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the preclinical and clinical pharmacokinetics and metabolism of DMT in healthy subjects.The physiochemical properties of DMT were determined using a series of in vitro experiments and its metabolic profile ...
Meghan Good, Zelah Joel, Tiffanie Benway, Carol Routledge, Chris Timmermann, David Erritzoe, Richard Weaver, Graham Allen, Charlotte Hughes, Helen Topping, Amy Bowman, Ellen James   +11 more
openaire   +2 more sources

The endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells

Frontiers in Neuroscience, 2016
N,N-dimethyltryptamine (DMT) is a potent endogenous hallucinogen present in the brain of humans and other mammals. Despite extensive research, its physiological role remains largely unknown.
Attila Szabo, Attila Szabo, Attila Szabo, Attila Kovacs, Jordi Riba, Jordi Riba, Srdjan Djurovic, Srdjan Djurovic, Eva Rajnavolgyi, Ede Frecska   +9 more
doaj   +1 more source

The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization

Frontiers in Pharmacology, 2016
Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual ...
Ede eFrecska, Petra eBokor, Michael eWinkelman   +2 more
doaj   +1 more source

Understanding Consumption of Illicit Drugs and New Psychoactive Substances in Australia by Triangulating Drug Checking and Wastewater-Based Epidemiology. [PDF]

Drug Test Anal
First Australian study combining wastewater‐based epidemiology and drug checking, demonstrating how complementary data sources enhance monitoring of illicit drugs and emerging psychoactive substances during high‐use periods. ABSTRACT Consumption of psychotropic drugs is a major economic and public health challenge in Australia.
Usman M, McLeod M, Nadarajan D, Clokey J, Prasad P, Verhagen R, Tscharke B, Quinto M, Bade R.   +8 more
europepmc   +2 more sources

Effects of N,N-dimethyltryptamine on electrically evoked responses in the cat visual system and modification by neuroleptic agents, [PDF]

, 1976
The effects of N,N-dimethyltryptamine on electrically evoked potentials in the visual system of the cat and the interaction of selected neuroleptic agents with dimethyltryptamine were studied.
Moore, R. H., Hatada, K., Domino, Edward F.   +2 more
core   +1 more source

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Brazilian Journal of Psychiatry, 2015
Objectives: Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions.
Flávia de L. Osório, Rafael F. Sanches, Ligia R. Macedo, Rafael G. dos Santos, João P. Maia-de-Oliveira, Lauro Wichert-Ana, Draulio B. de Araujo, Jordi Riba, José A. Crippa, Jaime E. Hallak   +9 more
doaj   +1 more source

Psychedelics: A new era of treatment?

European Psychiatry, 2021
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj   +1 more source

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms

European Psychiatry, 2022
Introduction The 5-HT2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens,
P. Chue, A. Andreiev, E. Bucuci, C. Els, J. Chue   +4 more
doaj   +1 more source